Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
EVO is expected to report earnings to fall 91.85% to -1 cents per share on May 06
Q1'25
Est.
$-0.01
Q4'24
Missed
by $0.09
Q3'24
Est.
$-0.12
Q2'24
Missed
by $0.26
Q1'24
Est.
$-0.06
The last earnings report on April 17 showed earnings per share of -13 cents, missing the estimate of -3 cents. With 21.00K shares outstanding, the current market capitalization sits at 2.77B.